The Laboratory for Translational Cancer Immunology develops immunotherapies for malignant neoplasia, with a special focus on acute leukemia and B-cell lymphoma. We seek to better understand mechanisms of action and resistance with the goal to identify predictive biomarkers for selecting the suitable immunotherapy for each individual patient.
Immunotherapy represents a promising alternative strategy for the eradication of refractory malignant cells. In recent years numerous immunotherapeutic approaches have been developed, most of which concentrate on the activation and recruitment of T cells.
Follow the links to learn more about our major research topics: